Federal Register / Vol. 72, No.
127 / Tuesday, July 3, 2007 / Notices
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12950 Filed 7–2–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 17, 2007,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Codeine (9050), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substance as an
intermediate to other opiates and supply
as API to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12952 Filed 7–2–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
jlentini on PROD1PC65 with NOTICES
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 19, 2007,
VerDate Aug<31>2005 17:57 Jul 02, 2007 Jkt 211001
36481
Dade Behring Inc., 100 GBC Drive,
MS514, Post Office Box 6101, Attention:
RA/QS, Newark, Delaware 19714–6101,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Drug
Tetrahydrocannabinols (7370) .....
Benzoylecgonine (9180) ...............
Morphine (9300) ...........................
The company plans to produce the
listed controlled substances in bulk to
be used in the manufacture of reagents
and drug calibrator/controls for DEA
exempt products.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12949 Filed 7–2–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated November 21, 2006
and published in the Federal Register
on December 1, 2006, (71 FR 69590),
Hospira, Inc., 1776 North Centennial
Drive, McPherson, Kansas 67460–1247,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
Remifentanil (9739), a basic class of
controlled substance listed in schedule
II.
PO 00000 Frm 00063 Fmt 4703 Sfmt 4703
The company plans to import
Remifentanil for use in dosage form
manufacturing.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Hospira, Inc to import the basic classes
of controlled substances is consistent
with the public interest and with United
Schedule States obligations under international
treaties, conventions, or protocols in
I effect on May 1, 1971, at this time. DEA
II has investigated Hospira, Inc to ensure
II
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and section 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic class of controlled
substance listed.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12953 Filed 7–2–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
This is notice that on February 12,
2007, Johnson Matthey Inc.,
Pharmaceutical Materials, 2003 Nolte
Drive, West Deptford, New Jersey 08066,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as an importer of Coca
Leaves (9040), a basic class of controlled
substance listed in schedule II.
The company plans to import the
listed controlled substance to
manufacture bulk Cocaine HCL for sale
to finished dosage form manufacturers.
As noted in a previous notice
published in the Federal Register on
September 23, 1975, (40 FR 43745), all
applicants for registration to import a
basic class of any controlled substances
in schedule I or II are, and will continue
to be, required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
E:\FR\FM\03JYN1.SGM 03JYN1
 36482 Federal Register / Vol. 72, No. 127 / Tuesday, July 3, 2007 / Notices
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12941 Filed 7–2–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 13, 2007,
Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066–1742, made application by letter
to the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug
Cocaine (9041) .............................
Ecgonine (9180) ...........................
The company plans on producing
cocaine for sale to its customers, who
are final dosage manufacturers. The
ecgonine is formed during the
manufacturing process for cocaine.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement Administrator,
Office of Diversion Control, Federal
Register Representative (ODL),
Washington, DC 20537; or any being
sent via express mail should be sent to
Drug Enforcement Administration,
Federal Register Representative (ODL);
2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
jlentini on PROD1PC65 with NOTICES
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12947 Filed 7–2–07; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005 17:57 Jul 02, 2007 Jkt 211001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to Title 21 Code of Federal
Regulations 1301.34 (a), this is notice
that on February 2, 2007, Lipomed, Inc.,
One Broadway, Cambridge,
Massachusetts 02142, made application
by renewal to the Drug Enforcement
Administration (DEA) for registration as
an importer of the basic classes of
controlled substances listed in
schedules II:
Drug
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
Methaqualone (2565) ...................
Gamma Hydroxybutyric Acid
(2010).
Lysergic acid diethylamide (7315)
2,5–Dimethoxy-4-(n)-
propylthiophenethylamine
(7348).
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5–Trimethoxyamphetamine
Schedule (7390).
4–Bromo-2,5-
II dimethoxyamphetamine (7391).
II 4–Bromo-2,5-
dimethoxyphenethylamine
(7392).
4–Methyl-2,5-
dimethoxyamphetamine (7395).
2,5–Dimethoxyamphetamine
(7396).
2,5–Dimethoxy-4-
ethylamphetamine (7399).
3,4–Methylenedioxyamphetamine
(7400).
3,4–Methylenedioxy-N-
ethylamphetamine (7404).
3,4–
Methylenedioxymethamphetam-
ine (7405).
4–Methoxyamphetamine (7411) ...
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Acetyldihydrocodeine (9051) ........
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Normorphine (9313) .....................
Pholcodine (9314) ........................
Tilidine (9750) ...............................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
PO 00000 Frm 00064 Fmt 4703 Sfmt 4703
Drug Schedule
Ethylmorphine (9190) ................... II
Hydrocodone (9193) ..................... II
Levorphanol (9220) ...................... II
Meperidine (9230) ........................ II
Methadone (9250) ........................ II
Dextropropoxyphene, bulk (non- II
dosage forms) (9273).
Morphine (9300) ........................... II
Thebaine (9333) ........................... II
Oxymorphone (9652) ................... II
Alfentanil (9737) ........................... II
Fentanyl (9801) ............................ II
Sufentanil (9740) .......................... II
The company plans to import
Schedule analytical reference standards for
distribution to its customers for research
I and analytical purposes.
I
I Any bulk manufacturer who is
I presently, or is applying to be,
I registered with DEA to manufacture
such basic classes of controlled
I substances listed in schedule I or II,
I which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C 952
(a)(2)(B) may file comments or
I
I objections to the issuance of the
I proposed registration and may, at the
I same time, file a written request for a
hearing on such application pursuant to
I
21 CFR 1301.43 and in such form as
I prescribed by 21 CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
I addressed, in quintuplicate, to the Drug
I Enforcement Administration, Office of
Diversion Control, Federal Register
I Representative (ODL), Washington, DC
20537; or any being sent via express
I mail should be sent to Drug
Enforcement Administration, Office of
I
Diversion Control, Federal Register
I Representative (ODL), 2401 Jefferson
Davis Highway, Alexandria, Virginia
22301; and must be filed no later than
I August 2, 2007.
I
I This procedure is to be conducted
I simultaneously with and independent
I of the procedures described in 21 CFR
I 1301.34(b), (c), (d), (e) and (f). As noted
I in a previous notice published in the
I Federal Register on September 23, 1975,
I
(40 FR 43745), all applicants for
I
II registration to import a basic class of
any controlled substances in schedule I
II
or II are and will continue to be required
II
II to demonstrate to the Deputy Assistant
II Administrator, Office of Diversion
II Control, Drug Enforcement
II
Administration, that the requirements
II
II for such registration pursuant to 21
U.S.C 958(a); 21 U.S.C 823(a); and 21
II
II CFR 1301.34(b), (c), (d), (e) and (f) are
II satisfied.
E:\FR\FM\03JYN1.SGM 03JYN1